Is Libida FDA Approved? What Is Approved, What Is Not, and What to Verify Before You Pay

No. Libida is not FDA-approved. It is a compounded sublingual prescription containing 1 mg bremelanotide and 20 IU oxytocin according to Inner Balance’s June 2026 FAQ. Vyleesi—not Libida—is the FDA-approved bremelanotide product, and only for premenopausal women. Confirm the pharmacy, checkout charge, and no-refund policy before paying.^[1][2]

That is the answer. Here is the part that took far too many pages to uncover: an approved ingredient does not turn a different compounded product into an approved drug. The FDA published a telehealth marketing reminder in June 2026 naming that exact kind of product-versus-ingredient confusion as a problem across compounded-drug advertising.^[3]

We earn nothing on Libida. We are not an Inner Balance affiliate. Links to Inner Balance are unpaid. Where another page contains affiliate links, we label that clearly. The answer above would be identical either way.

Is this page for you?

Best for you if:

• You are at checkout—or close—and want a straight regulatory answer before paying.
• You saw “FDA-approved ingredient” or “same active ingredient” and could not tell whether that meant Libida itself was approved.
• You want to compare Libida with Vyleesi, Addyi, or testosterone without blending approved and compounded products.
• You already ordered Libida and want a calm checklist for verifying the prescription, pharmacy, dose, billing, and safety information.

Not for you if:

• You want a full experience-and-policy review. Read our Libida review.
• You want every plan, tablet count, renewal charge, and unit-cost calculation. Read our Libida cost analysis.
• You are researching low desire broadly rather than this product’s approval status. Start with low libido and sexual health in menopause.
• You have chest pain, fainting, trouble breathing, a severe sudden headache, confusion, new bleeding after menopause, or another urgent symptom. This page is not the right starting point.

Quick name check: Libida is Inner Balance’s compounded prescription tablet. It is not the generic word libido, and it is not an over-the-counter libido supplement.

Libida and FDA approval at a glance

Libida is a compounded prescription product, not an FDA-approved drug. Inner Balance now publishes the formula and use limit, but it still does not publicly identify the dispensing pharmacy for a specific order, publish product-specific absorption data, or extend its refund guarantee to Libida.^[1][4]

Question	Answer	Evidence checked	Last checked
Is Libida FDA-approved?	No. It is compounded.	FDA compounding guidance; Inner Balance FAQ	August 2026
Is compounding automatically illegal?	No. Compounding can be lawful when federal and state conditions are met.	FDA; federal compounding law	August 2026
Is one ingredient in an approved product?	Yes. Bremelanotide is the active ingredient in Vyleesi.	Vyleesi prescribing information	August 2026
Is Vyleesi approved for postmenopausal women?	No. Its label is limited to premenopausal women with acquired, generalized HSDD.	Vyleesi prescribing information	August 2026
Is Libida’s formula public?	Provider-stated: 1 mg bremelanotide + 20 IU oxytocin per tablet.	Inner Balance FAQ dated June 14, 2026	August 2026
Is the exact dispensing pharmacy public?	Not on the Libida pages we reviewed. Confirm it for your order.	Inner Balance product page, FAQ, and terms	August 2026
Is insurance accepted?	No. Inner Balance’s terms describe a direct-pay service and say it does not accept insurance.	Inner Balance terms	August 2026
Is Libida clearly HSA/FSA eligible?	No. The company’s pages conflict.	Product page, Libida FAQ, dedicated HSA/FSA page	August 2026
Can you get a Libida refund under the guarantee?	No. The refund policy excludes Libida by name.	Inner Balance refund policy	August 2026
Can you cancel future subscription charges?	Yes, through the secure portal. Cancellation does not create a Libida refund.	Inner Balance terms and refund policy	August 2026
Is a state-availability list public?	Not on the Libida pages we found. Confirm prescribing and dispensing availability before paying.	Inner Balance terms and Libida pages	August 2026
Are Libida-specific labs listed as included or required?	No public Libida-specific lab panel or requirement found. Outside tests may create extra cost if ordered.	Inner Balance terms and product flow	August 2026

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Is Libida FDA approved?

No. Libida is a compounded prescription medication, and compounded drugs are not FDA-approved. FDA does not review the finished Libida product through a drug-approval application before marketing for safety, effectiveness, quality, dose, labeling, or manufacturing consistency. Vyleesi’s approval belongs to Vyleesi—not to every product containing bremelanotide.^[2][5]

Inner Balance’s own June 2026 FAQ says Libida contains the active ingredient used in an FDA-approved injectable and then identifies Libida itself as compounded. Its product page also carries a disclosure that the product is compounded individually and that the statements have not been evaluated by FDA.^[1][4]

So the company does disclose the distinction. Credit where it is due.

But the clearest answer—“No, Libida is not FDA-approved”—still is not the first sentence on the product page where a buyer sees the price and enters the purchase flow. Instead, the page uses “Same active ingredient” in its injection comparison. That molecule-level statement does not establish product-level approval, equivalence, absorption, safety, or effectiveness.^[4]

That gap between a disclosure that technically exists and an answer a buyer can instantly understand is the entire reason this page exists.

Is “off-label” the right description for Libida?

“Unapproved compounded drug” is the more precise FDA category. Off-label normally describes an FDA-approved product prescribed outside its approved indication, dose, route, or population. Libida has no FDA-approved label of its own, so calling the finished product merely “off-label” can hide the more important fact: it is compounded and unapproved.^[2]

That does not make it fake. It does not make every prescription unlawful. It tells you which evidence and oversight package does—and does not—exist for this exact product.

What does “not FDA-approved” actually mean?

It means FDA did not evaluate this exact finished formulation through the approval process. State pharmacy boards and, depending on the facility, FDA may still regulate or inspect parts of compounding practice. What is missing is product-specific premarket approval for Libida’s exact dose, two-drug combination, sublingual route, labeling, and evidence package.^[2][6]

For an FDA-approved drug, the public record can include:

• The exact active ingredient and strength
• The approved route and dosage form
• The population and condition studied
• Clinical trial methods and results
• Contraindications, warnings, adverse-event rates, and interactions
• Pharmacokinetic data showing how the product is absorbed and cleared
• Manufacturing controls and approved labeling
• Postmarketing safety changes and label revisions

For Libida, you can now look up the provider-stated ingredient amounts and use limit. You cannot look up an FDA-reviewed Libida label, a public approval review, a product-specific pharmacokinetic study, or a controlled trial of the exact 1 mg bremelanotide + 20 IU oxytocin sublingual tablet.

Compounded is also not the same as generic. An FDA-approved generic must meet approval requirements and demonstrate equivalence to its reference product. A compounded drug is not an approved generic and should not be described as one.^[2][3]

The one question that should drive your decision

FDA says compounded drugs should generally be used when a patient’s medical needs cannot be met by an available FDA-approved drug. That does not answer your decision automatically. It gives you the right question:^[2]

Can an FDA-approved option meet my need—or is there a patient-specific reason the approved route, dose, ingredient set, or treatment model does not fit me?

That answer depends on your life stage, diagnosis, cardiovascular history, medication list, tolerance for injections or nightly dosing, prior response, and whether pain, dryness, another medication, or another health issue is driving the change in desire.

Is FDA approval always the better choice?

No. “FDA-approved” is not a synonym for “better for you,” and we are not going to pretend it is. Approval gives you product-specific evidence, a public label, standardized manufacturing requirements, and a defined benefit-risk record. It does not erase side effects, guarantee benefit, or make one route fit every patient.

Addyi is a 100 mg pill taken every night. Its current label carries a boxed warning for severe low blood pressure and fainting in certain settings. It is contraindicated with moderate or strong CYP3A4 inhibitors and with any degree of liver impairment. If you drink one or two standard drinks, the label says to wait at least two hours before the bedtime dose; after three or more drinks, skip that night’s dose. Stop after eight weeks if symptoms have not improved.^[7]

Vyleesi is an injection. Its label reports nausea in 40% of treated participants in the pivotal trials, compared with 1.3% on placebo. It temporarily raises blood pressure and lowers heart rate after each dose, is contraindicated with uncontrolled hypertension or known cardiovascular disease, and is not indicated for postmenopausal women.^[5]

Testosterone for postmenopausal HSDD has a different problem: the international consensus identifies postmenopausal HSDD as the only evidence-based indication for testosterone therapy in women, but the United States has no testosterone product approved specifically for women. Testosterone is a Schedule III controlled substance, requires a prescription and appropriate monitoring, and consensus guidance does not recommend compounded testosterone when an authorized equivalent preparation is available.^[8][9]

If anyone tells you the approved options are simply “the good ones” and compounded options are simply “the bad ones,” they have flattened a real clinical decision into a slogan.

What approval buys you is still substantial: a public dose, a public label, product-specific trials, measurable adverse-event rates, defined contraindications, manufacturing controls, and a record that can be independently checked. Approval status does not reduce the decision to “safe” versus “risky.” It tells you how much product-specific evidence and federal review exist before you and your clinician decide what trade-off is acceptable.

Why does Vyleesi’s approval not cover Libida?

Because FDA approves a specific finished drug, not an ingredient name in the abstract. Vyleesi and Libida differ in every approval dimension that matters here: ingredient set, strength, route, dosage form, labeled population, and manufacturing pathway. Sharing bremelanotide does not bridge those differences.^[1][5]

Approval dimension	Vyleesi — FDA-approved product	Libida — compounded product
Active ingredient set	Bremelanotide only	Bremelanotide + oxytocin
Strength	1.75 mg/0.3 mL	Provider-stated 1 mg bremelanotide + 20 IU oxytocin
Route	Subcutaneous injection	Sublingual tablet dissolved under the tongue
Dosage form	Single-use autoinjector	Compounded tablet/lozenge
Approved population	Premenopausal women with acquired, generalized HSDD meeting label criteria	No FDA-approved population; prescriber decides whether to use the compounded product
Manufacturing and quality framework	Approved product manufactured under federal drug-manufacturing requirements	Depends on the dispensing compounder and whether the prescription is filled under a 503A or 503B pathway

That is six of six, not a technicality.

Route alone matters. The amount of drug reaching the bloodstream—and how quickly—can change substantially between an injection and a tablet held under the tongue. Vyleesi’s 1.75 mg injection data cannot tell you the exposure produced by Libida’s 1 mg sublingual bremelanotide. Adding oxytocin introduces another ingredient that was not part of Vyleesi’s approval package.

Inner Balance publishes no public pharmacokinetic or absorption study for the exact Libida tablet. That is not proof the product fails. It is the evidence boundary.

Use this approval decoder before you accept any telehealth claim

Claim you see	What it proves	What it does not prove
“Contains an FDA-approved ingredient”	One ingredient appears in at least one approved product	The compounded product is approved, equivalent, equally absorbed, equally effective, or equally safe
“Same active ingredient”	The named molecule may be present in both products	Same dose, route, formulation, quality controls, indication, or clinical outcome
“Clinician-prescribed”	A licensed prescriber may have authorized a prescription	FDA approval of the finished product
“Made by a U.S. pharmacy”	A U.S. pharmacy may compound or dispense it	That the pharmacy is “FDA-approved” or that every batch was reviewed by FDA
“Third-party tested”	Testing may have occurred	What was tested, which lab performed it, the acceptance limits, or the lot-level result—unless those records are provided
“Research-backed ingredient”	Evidence may exist for an ingredient or another product	Evidence for this exact combination, dose, and route

This is not another summary. It is a claim decoder you can use on the next product too.

What is actually in Libida?

Inner Balance’s June 14, 2026 FAQ states that each Libida tablet contains 1 mg bremelanotide and 20 IU oxytocin, with natural wild-berry and marshmallow flavoring, silica, and mannitol. Treat those amounts as provider-stated until they match the prescription label and dispensing pharmacy information on your own order.^[1]

A correction to our earlier Libida research belongs here: previous versions of our coverage said the dose was not public. That was true when those pages were checked. It is not true now. Inner Balance published the formula in its help center, and we are correcting the record rather than quietly carrying stale information forward.

What remains true is narrower—and more useful: the dose is available in a help-center article, not presented prominently beside the product price and purchase decision.

What each ingredient’s FDA record actually shows

Bremelanotide is a melanocortin receptor agonist. Vyleesi’s label states that the mechanism by which it improves HSDD is unknown. The approved evidence applies to a 1.75 mg subcutaneous bremelanotide product in the labeled premenopausal population—not to a 1 mg sublingual combination.^[5]

Oxytocin is a peptide hormone with FDA-approved injectable products used in obstetric care. We found no FDA-approved U.S. oxytocin product labeled for low sexual desire and no current FDA-approved sublingual oxytocin product.^[10]

Ingredient or combination	Current FDA-approved U.S. product relevant to this question	Approved route	Approved use relevant here	What it means for Libida
Bremelanotide	Vyleesi	Subcutaneous injection	Acquired, generalized HSDD in premenopausal women meeting label criteria	Confirms approval of Vyleesi, not Libida
Oxytocin	Oxytocin injection products	IV or IM, depending on label	Obstetric indications such as labor management and control of postpartum bleeding	Does not support approval for low desire or sublingual use
Bremelanotide + oxytocin	None found	—	—	The exact Libida combination is not FDA-approved
Either ingredient in a sublingual product	None found	—	—	The Libida route is outside current FDA-approved products for these ingredients

Three facts fall out of that table:

1. No FDA-approved product combines bremelanotide and oxytocin.
2. No FDA-approved U.S. product we found delivers either ingredient sublingually.
3. The clinical evidence for one approved ingredient cannot be transferred to the finished combination without product-specific data.

And now the fair version

A route or combination that no approved product offers can be exactly why compounding is considered. A patient who cannot use injections, cannot tolerate an approved product, needs a different formulation, or has another documented clinical need is having a legitimate medical conversation—not automatically falling for a trick.^[2]

The existence of that legitimate pathway does not answer whether you need it. That is what the prescriber should be able to explain.

Is Libida the same as Vyleesi?

No. Libida and Vyleesi share bremelanotide, but they are not the same product, not approved generics of one another, and not therapeutically interchangeable on the evidence available. Libida adds oxytocin, changes the dose, changes the route, and has no FDA-reviewed label or product-specific trial package.^[1][5]

Decision fact	Libida	Vyleesi	Addyi
FDA-approved finished product?	No — compounded	Yes	Yes
Active ingredient(s)	Bremelanotide + oxytocin	Bremelanotide	Flibanserin
Dose	Provider-stated 1 mg + 20 IU	1.75 mg/0.3 mL	100 mg
Route	Sublingual tablet	Subcutaneous injection	Oral tablet
Schedule	On demand	On demand	Every night at bedtime
Labeled population	No FDA-approved population	Premenopausal women with acquired, generalized HSDD	Women under 65 with acquired, generalized HSDD
Postmenopausal FDA indication	None	No	Yes, if under 65
Public product-specific trials	None located	Yes	Yes
Public pharmacokinetic data for exact product	None located	Yes	Yes
Published use limit	Provider guidance: no more than 1 dose per 72 hours and no more than 10 per month	Label: no more than 1 dose per 24 hours; more than 8 per month not recommended	1 tablet nightly; discontinue after 8 weeks if no improvement
Boxed warning	No FDA label exists	No	Yes — hypotension and syncope in certain settings
Federal controlled-substance schedule	Disclosed ingredients are not listed as federally scheduled drugs	Not federally scheduled	Not federally scheduled

Notice the monthly ceilings: Inner Balance says no more than 10 Libida doses per month; Vyleesi’s label says more than eight doses per month is not recommended.^[1][5]

We are going to show you those numbers and stop there. They do not create a head-to-head risk comparison. The products differ in route, strength, ingredients, evidence, and labeling. Anyone who converts “10 versus 8” into proof that one is safer, stronger, or more effective is inventing a conclusion.

Is Libida legal?

Compounding can be lawful when the prescription and compounder meet the applicable federal and state requirements. “Not FDA-approved” does not mean “black market.” But approval status alone also cannot prove that a specific prescription, pharmacy, shipment, or formulation complies with every requirement.^[11]

Federal law provides pathways for patient-specific compounding by qualifying pharmacies under section 503A and for qualifying outsourcing facilities under section 503B. Those pathways have different conditions, exemptions, oversight, and manufacturing requirements.^[6][11]

The public Libida pages do not tell us which named pharmacy will fill a particular order or which pathway applies to that fill. That means the responsible answer is not a blanket “everything is legal.” It is:

Libida can be lawfully prescribed and compounded, but verify the dispensing pharmacy, its license, and the pathway for your own prescription.

What about the “essentially a copy” rule?

Federal law restricts certain compounding of products that are essentially copies of commercially available approved drugs. For 503A compounding, FDA guidance recognizes a patient-specific significant-difference route when the prescriber determines that the compounded preparation produces a significant difference for the identified patient.^[11]

Libida adds oxytocin and changes the dose, route, and dosage form from Vyleesi. Whether a particular prescription is legally treated as an essentially identical copy is a fact-specific regulatory question, not something this page can decide from a marketing page.

The useful question for your prescriber is still direct:

“Why is this compounded sublingual combination the appropriate choice for my situation instead of an available FDA-approved option?”

A clear medical answer is more valuable than a slogan about ingredients.

Is there an FDA-approved option for your life stage?

The answer depends on your age, menopause stage, diagnosis, and cause of low desire. Vyleesi remains limited to premenopausal women. Addyi’s current U.S. label covers women under 65 with acquired, generalized HSDD, including postmenopausal women, provided the low desire is not due to another condition, relationship problem, medication, or drug.^[5][7]

If you are premenopausal

Two FDA-approved products may enter the discussion:

• Vyleesi: 1.75 mg injection used as needed at least 45 minutes before anticipated sexual activity. No more than one dose in 24 hours; more than eight doses per month is not recommended.
• Addyi: 100 mg oral tablet taken nightly at bedtime. Stop after eight weeks if there is no improvement.

Both labels are for acquired, generalized HSDD—low desire that is a change from the past, occurs across situations or partners, causes distress, and is not better explained by another medical or psychiatric condition, relationship problem, medication, or drug.^[5][7]

If you are postmenopausal and under 65

Addyi is now an FDA-approved option. Its current label includes women under 65 rather than limiting treatment to premenopausal women. The postmenopausal efficacy study included 902 naturally postmenopausal participants under 65: 447 received Addyi and 455 received placebo.^[7]

That corrects a common stale claim—and one error in the draft version of this page, which counted only the 447 women assigned to Addyi as if that were the entire trial.

The trade-off is real: Addyi is nightly rather than on demand, carries a boxed warning for hypotension and syncope in certain settings, has alcohol-timing instructions, is contraindicated with moderate or strong CYP3A4 inhibitors and any liver impairment, and should be stopped after eight weeks without improvement.^[7]

If you are 65 or older

Neither Addyi’s label nor Vyleesi’s label covers you. That does not mean no care exists. It means there is no FDA-approved HSDD medication labeled for this age group, and the next step belongs with a clinician who can assess symptoms, medications, cardiovascular risk, pain, genitourinary symptoms, and other causes rather than forcing you through a product quiz.

If you had surgical menopause

Addyi’s indication is written broadly for women under 65, but its labeled postmenopausal study was in naturally postmenopausal women. Your hormone status, surgery, age, medications, cancer history, and symptoms change the evidence conversation. Do not self-sort from the word “postmenopausal” alone.

What about testosterone after menopause?

The global consensus states that the only evidence-based indication for testosterone therapy in women is HSDD in postmenopausal women after formal assessment. Four facts keep that sentence from becoming a casual shopping recommendation:^[8]

1. There is no FDA-approved testosterone product specifically for women in the United States.
2. Testosterone is a Schedule III controlled substance under federal law.^[9]
3. It requires a prescription, clinical evaluation, dosing that keeps concentrations in the physiologic female range, and monitoring.
4. The consensus does not recommend compounded testosterone when an approved equivalent preparation is available; pellets and injections that produce supraphysiologic concentrations are also outside the recommendation.

That is not a DIY route and not a same-day guarantee.

Want an FDA-approved-leaning care path rather than a compounded-first program? Read our verified Midi Health review to understand its insurance model, state access, visit pricing, and medication approach. That page contains labeled affiliate links; this Libida page does not earn from Inner Balance.

What if medication, pain, or another condition is the real cause?

Vyleesi and Addyi are labeled only for acquired, generalized HSDD that is not caused by another medication, a medical or psychiatric condition, or relationship problems. If the drop in desire began after a medication change, with painful sex, alongside new mood symptoms, or with another health change, buying a desire drug before investigating the cause may be the wrong—and more expensive—first move.^[5][7]

Antidepressants and other medications

SSRIs and SNRIs can cause sexual side effects. Other medications can also affect desire, arousal, orgasm, energy, or comfort. If the timing lines up with starting a medicine or changing a dose, bring that timeline to the prescriber. Do not stop a medication abruptly or alter it from an article.

Pain, dryness, and genitourinary symptoms

Painful sex and dryness may reflect genitourinary syndrome of menopause, pelvic-floor problems, infection, vulvar disease, medication effects, or another cause. Wanting to avoid pain is not a desire failure. Assessing and treating the pain may change the libido question completely.

Mood, sleep, thyroid disease, anemia, and general health

Depression, anxiety, sleep disruption, thyroid disease, anemia or iron deficiency, chronic illness, and exhaustion can all belong in the differential when the history points there. A clinician may decide that an exam, medication review, or targeted testing matters more than a broad “hormone panel.”

Relationship and life context

Sometimes desire is responding accurately to stress, resentment, fear, lack of privacy, caregiving load, or relationship dynamics. That does not make the symptom imaginary. It means the cause determines the tool.

None of this tells you to go home and try harder. It tells you not to spend $199, $249, or $299 on the wrong explanation.

Not sure which branch fits your situation? Get your personalized HRT starting-point plan with Find My HRT Path →

The tool routes by symptoms, stage, state, treatment preferences, insurance, and safety flags. It also tells you when online care is not the right starting point. It takes about 90 seconds, requires no email, and does not diagnose or prescribe.

Why is Libida’s FDA status so confusing online?

Because ingredient-level claims can land in a reader’s mind as product-level claims. In June 2026, FDA published a telehealth marketing reminder describing five misleading patterns in compounded-drug promotion. The page focuses heavily on compounded GLP-1 marketing, but the product-versus-ingredient principles are useful well beyond that category.^[3]

FDA’s list does not establish that Inner Balance violated the law. The FDA page does not identify Inner Balance; this is an applied checklist, not an enforcement finding.

FDA marketing problem	What it can look like	What Inner Balance’s public Libida material says	The question that clears it up
Branding that obscures who compounds the drug	A telehealth brand dominates while the actual compounder is unclear	Libida is branded by Inner Balance; the Libida pages reviewed do not name the pharmacy for a specific order	“Which pharmacy compounds and dispenses my prescription?”
Calling a compounded drug a generic or the same as an approved drug	“Generic Vyleesi” or “the same as Vyleesi”	The product comparison says “Same active ingredient,” but Libida adds oxytocin and uses another dose and route	“Is this statement about one molecule or the finished product?”
Claiming FDA approval or evaluation	“FDA-approved compounded product”	Inner Balance’s footnote says Libida is compounded and its statements were not evaluated by FDA	“Is the finished product approved, or only an ingredient in another product?”
Claiming the compounded product is clinically proven to match an approved drug	Borrowing trial results without naming the studied product and route	The FAQ says the randomized evidence comes from the approved injectable form; that is the correct boundary	“Which exact product, route, dose, and population were studied?”
Calling the source an FDA-approved or FDA-licensed pharmacy	“FDA-approved pharmacy”	Inner Balance uses “FDA-regulated pharmacy” on an education page and uses different 503A/503B descriptions on broader treatment pages	“What is the pharmacy’s legal name, license, and 503A or 503B status for this fill?”

Hold this page to the same standard. When we say “Vyleesi’s trials,” we mean Vyleesi. When we say “Inner Balance reports,” we mean provider-stated. When no exact-product study exists in the public record we searched, we say that instead of filling the gap with confidence.

Who makes Libida, and is the pharmacy FDA-approved?

No pharmacy is “FDA-approved,” and FDA says it does not approve or license facilities. A state board may license a pharmacy. A 503B outsourcing facility may register with FDA and be inspected. Those are real forms of oversight, but none turns a facility into an FDA-approved pharmacy.^[3][6]

Inner Balance says prescriptions ship from a U.S. pharmacy, but the public Libida pages we reviewed do not identify the dispensing pharmacy for a specific order. Inner Balance’s broader pages also use both 503A and 503B descriptions in different product contexts. Its About page displays a 503A pharmacy badge, while its Oestra product page describes a 503B facility. Those statements may refer to different products or partners; they do not tell you which pathway applies to your Libida prescription.^[20][21]

Pathway	What it generally means	Primary oversight and standards	What registration does not mean
503A	Traditional patient-specific compounding by a qualifying pharmacy or physician	Primarily state pharmacy-board oversight; exempt from federal current good manufacturing practice requirements when statutory conditions are met	The finished drug is not FDA-approved
503B	Compounding by an outsourcing facility that registers with FDA	Subject to current good manufacturing practice requirements and risk-based FDA inspection, plus other federal conditions	Registration is not FDA approval of the facility or each drug

How to verify the prescription in ten minutes

1. Ask for the dispensing pharmacy’s legal name and address before payment.
2. Ask whether your prescription will be filled by a 503A pharmacy or a 503B outsourcing facility.
3. Check the pharmacy license through your state board of pharmacy.
4. For a claimed 503B facility, check FDA’s registered outsourcing-facility list and inspection records. Registration alone is not a clean bill of health; read the current status.
5. Check the prescriber’s license in your state.
6. Read the package label before use. Confirm your name, prescriber, pharmacy, ingredient names and strengths, directions, storage instructions, beyond-use date, and pharmacy contact information. Label requirements vary by state, but missing or conflicting basics deserve a call.
7. Compare the label with the public formula. If the amounts are not 1 mg bremelanotide and 20 IU oxytocin, ask why before taking it.

That last step is almost free, and it answers more than another hour of marketing copy.

Is Libida safe, and does it actually work?

Approval status, safety, and effectiveness are three different questions. No FDA approval means FDA did not evaluate this exact product; it does not prove harm. It also does not prove benefit. The evidence has to be kept in three separate layers.

Layer 1: What Vyleesi’s FDA-reviewed label reports

For the approved 1.75 mg bremelanotide injection, the label reports:^[5]

• Nausea in 40% of Vyleesi-treated participants versus 1.3% on placebo in the pivotal trials
• Flushing in 20.3% versus 0.3%
• Headache in 11.3% versus 1.9%
• A transient blood-pressure increase and heart-rate decrease after each dose, usually resolving within 12 hours
• Contraindication with uncontrolled hypertension or known cardiovascular disease
• Focal hyperpigmentation in 1% of participants using up to eight doses per month, including the face, gums, and breasts; resolution was not confirmed in every patient
• Potential effects on absorption of oral medicines because Vyleesi can slow gastric emptying
• A specific warning to avoid orally administered naltrexone products used for alcohol or opioid addiction because Vyleesi may reduce naltrexone exposure

Those are Vyleesi rates and warnings.

Layer 2: What Inner Balance says about Libida

Inner Balance lists mild nausea, flushing, headache, a slight temporary blood-pressure increase, and rare pigmentation on the product page. It tells patients not to use Libida with uncontrolled blood pressure, untreated heart disease, or during pregnancy, and its FAQ says it is not recommended while breastfeeding because the exact product has not been studied in that setting.^[1][4]

The page’s “about 1%” pigmentation claim appears to borrow the Vyleesi injection rate. That number should not be presented as an established Libida incidence without Libida-specific data. The same applies to any promise that pigmentation is harmless, temporary, or reliably reversible: Vyleesi’s label says resolution was not confirmed in some patients.^[5]

The wording difference on cardiovascular disease matters too. Vyleesi is contraindicated with known cardiovascular disease. Inner Balance’s product page says untreated heart disease. A person with treated heart disease should not assume that provider wording clears the risk; ask the prescriber directly.

Layer 3: What nobody can establish from the public evidence

Vyleesi’s 40% nausea rate is not Libida’s rate. Its 1% hyperpigmentation rate is not automatically Libida’s rate. Libida changes the dose, route, formulation, and ingredient set. There is no public head-to-head study and no public controlled trial of the exact Libida combination.

That also cuts the other way. Nobody can promise the sublingual tablet is gentler merely because it avoids a needle. Route changes exposure; it does not automatically reduce every systemic effect.

Does bremelanotide work?

In the phase 3 RECONNECT trials, the approved bremelanotide injection significantly improved the co-primary measures of sexual desire and distress related to low desire compared with placebo. The trials did not show a statistically significant difference between treatment groups in the change in satisfying sexual events associated with study drug.^[12]

That does not mean Vyleesi “failed.” Desire and distress were the primary efficacy outcomes tied to HSDD. But the satisfying-sexual-events result is exactly the kind of inconvenient fact a buyer deserves before someone turns “research-backed ingredient” into “this tablet will improve my sex life.”

Does oxytocin improve sexual function?

A randomized, placebo-controlled crossover trial in 30 premenopausal and postmenopausal women tested long-term intranasal oxytocin. Sexual function and depressive symptoms improved over time in both oxytocin and placebo periods, with no significant treatment effect.^[13]

That study used a nasal spray, not a sublingual tablet, and oxytocin alone rather than Libida’s combination. It cannot prove Libida does not work. It can tell you that the simple “bonding hormone therefore better sexual function” story did not produce a clear treatment effect in that trial.

What evidence exists for the exact Libida product?

Inner Balance cites internal experience involving more than 10,000 women and publishes testimonials. We did not locate a public protocol, comparison group, prespecified endpoints, adverse-event table, statistical analysis, or peer-reviewed paper for the exact Libida product as of August 2026.^[4]

A testimonial can tell you what one customer says happened. It cannot establish FDA status, typical effectiveness, incidence of side effects, or causation. That is why this page intentionally does not use customer quotes as medical evidence.

Stop reading and get care: Call 911 or seek urgent care for chest pain, fainting, trouble breathing, a severe sudden headache, confusion, or another medical emergency. Contact the prescriber or pharmacist promptly for a reaction that worries you. Start with an in-person clinician rather than an online product form for new bleeding after menopause, pelvic pain, a complex cancer history, uncontrolled blood pressure, known cardiovascular disease, pregnancy, or a sudden unexplained change in libido.

How much does Libida cost, and can you get a refund?

Inner Balance’s product page advertises Libida “from $99.70/mo,” but its own pricing content lists actual charges of $199, $249, or $299 depending on quantity and billing interval. Libida is excluded from the refund guarantee. Confirm the tablet count, first charge, renewal charge, billing date, and one-time-versus-recurring status at checkout.^[4][14]

The pricing language is not fully reconciled across Inner Balance’s pages:

Official Inner Balance source	Published statement	What you should do
Libida product page	“From $99.70/mo,” “20% off,” and “Cancel anytime”	Treat as advertising, not a confirmed checkout charge
2026 pricing guide	$249 one-time for 10; $199 monthly for 10; $249 for 20 every two months; $299 for 30 every three months	Verify which plan still appears at checkout
Another Inner Balance guide	Refers to $249 for 20 but also says $279 is charged every two months	Do not choose between the conflicting figures yourself; save the checkout screen[22]
Terms	Monthly, two-month, and three-month fees are charged in advance; one-time prescriptions are billed upfront	Confirm the amount put at risk before clinical approval and pharmacy processing

“From $99.70 a month” appears to normalize a multi-month charge into a monthly equivalent. That is not the same as the amount charged to your card.

The refund exclusion, plainly

Inner Balance’s refund policy says refunds apply only to qualifying Oestra subscription fees and qualifying BodyMatched face-cream purchases. Its exclusion list names Libida directly.^[15]

That is the damaging policy fact:

You can cancel future Libida subscription charges, but the guarantee does not refund the Libida purchase you already made.

Cancellation and refund are not synonyms. The terms say cancellation is handled through the secure account portal. The refund policy says cancellation does not automatically process a refund. For Libida, the product exclusion remains.^[15][16]

The practical move is not complicated: choose the smallest commitment whose full charge you can afford to lose, confirm it is one-time or recurring, and save the checkout terms before submitting payment. The lowest per-tablet price is not the lowest-risk first purchase when there is no product guarantee.

HSA and FSA: the provider contradicts itself

Inner Balance source	Current statement
Libida product page	Displays “HSA/FSA Eligible”
Libida FAQ	Says some clients may be able to use HSA/FSA funds depending on the plan
Dedicated HSA/FSA page	Says “Currently, only OESTRA is eligible for HSA/FSA payments”
Refund policy	Says HSA/FSA purchases can be eligible for refund generally, while separately excluding Libida from refunds
Dedicated HSA/FSA page	Says HSA/FSA purchases are non-refundable

We are not going to pick the convenient side of a provider contradiction.^[1][4][17]

If pre-tax dollars are what make this feel affordable, get written confirmation from Inner Balance and your plan administrator before paying. A card processing successfully does not establish tax eligibility, and the company’s own pages do not give one consistent answer.

Insurance, labs, and state availability

Inner Balance’s terms say the service does not accept insurance and tells members not to submit claims to commercial insurance, Medicare, Medicaid, or another government program. The Libida FAQ’s softer phrase—“insurance is unlikely to cover”—does not override the direct-pay terms.^[1][16]

The public Libida flow does not list a required or included lab panel. Inner Balance’s terms allow a clinician to recommend outside diagnostic tests or services that create separate bills. Do not assume “no labs shown” means “no additional testing can be required.”^[16]

The terms also say some services may not be available in every state. We found no complete Libida state list. Confirm that a clinician licensed in your state can prescribe and that the pharmacy can dispense to your state before the charge becomes non-refundable.^[16]

What do the approved options currently cost?

Manufacturer programs can make approved products cheaper than a compounded cash-pay option for an eligible patient:

• Addyi: the official program currently advertises $149 per month cash through PhilRx or as little as $20 per month with qualifying commercial insurance coverage. Eligibility and terms apply.^[18]
• Vyleesi: the official program currently advertises $99 for a four-dose box without coverage through its designated pharmacy pathway, or as little as $0 for eligible commercially insured patients. Government-funded coverage excludes a patient from the assistance program; confirm the full current terms.^[19]

Those are manufacturer-program prices, not guaranteed out-of-pocket costs for every patient. They can change. They also do not include every possible visit, prior-authorization, or diagnostic cost.

Want the full plan-by-plan Libida math before risking a non-refundable charge? Read the Libida cost analysis and compare the actual charge, tablet count, renewal interval, and cost per usable dose—not the monthly-equivalent headline.

What should you ask before paying for Libida?

Ask eight questions: four for the care team, three for the prescriber, and one for the pharmacy. If the answers remain vague after the company has your clinical and state information, that is decision-grade information. “FDA-approved ingredient” is not a substitute for product-level answers.

Ask the care team

1. Which legal pharmacy name will compound and dispense my prescription, and what state is it licensed in?
2. Will this prescription be filled under a 503A or 503B pathway?
3. What exactly will my card be charged today, how many tablets are included, is it one-time or recurring, what is the next billing date, and what is the renewal amount?
4. Will you confirm in writing whether Libida is HSA/FSA eligible under your current policy, given that your product page and dedicated HSA/FSA page conflict?

Ask the prescriber

1. Given my blood pressure, cardiovascular history, medications, pregnancy potential, and breastfeeding status, is this appropriate for me?
2. Could pain, dryness, an antidepressant or other medication, thyroid disease, anemia, sleep disruption, mood, or another condition better explain the change in desire?
3. Why is this compounded sublingual combination the right choice for me instead of an FDA-approved option or treatment of the underlying cause?

Ask the pharmacy when the prescription arrives

1. Does my label confirm the pharmacy, prescriber, 1 mg bremelanotide, 20 IU oxytocin, directions, storage, beyond-use date, and a working pharmacy phone number—and can you explain any difference?

Copy those questions into the secure portal before checkout. You do not need a polished speech. You need answers you can save.

If you already bought Libida

Nothing about the phrase “not FDA-approved” is, by itself, a reason to panic.

Do not assume from this page that the package is authentic, counterfeit, correctly filled, or incorrectly filled. Check the label. Verify the named pharmacy. Match the ingredients and strengths. Read the directions and warnings. Call the dispensing pharmacist before use if the package lacks basic identifying information or anything conflicts with what you were prescribed.

If the prescription is helping and your prescriber has reviewed your medical history, medication list, blood pressure, adverse effects, and alternatives, continued use is a clinical decision—not something you need to apologize for. Open eyes are the point of this page, not shame.

What did The HRT Index actually verify?

For this update, we separated primary regulatory evidence, approved-drug labels, peer-reviewed trials, and provider-stated commercial facts. We did not enroll, receive a tablet, inspect a patient-specific label, test a lot, or interview the dispensing pharmacist. The unverified items stay visible rather than being guessed.

Verified from primary or official sources

• FDA says compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality.
• Vyleesi is an FDA-approved 1.75 mg/0.3 mL subcutaneous bremelanotide product for premenopausal women with acquired, generalized HSDD meeting label criteria.
• Vyleesi is not indicated for postmenopausal women or men.
• Addyi’s current indication covers women under 65 with acquired, generalized HSDD meeting label criteria.
• The Addyi postmenopausal study enrolled 902 women under 65: 447 on Addyi and 455 on placebo.
• Testosterone is a Schedule III controlled substance in the United States.
• Inner Balance’s June 2026 FAQ publishes the Libida formula as 1 mg bremelanotide + 20 IU oxytocin and says not to exceed one dose per 72 hours or 10 per month.
• Inner Balance’s terms say it does not accept insurance and allows cancellation through the secure portal.
• Inner Balance’s refund policy excludes Libida by name.
• Inner Balance’s product, HSA/FSA, refund, pricing, and help-center pages contain material contradictions.^{[1][4][14][15][17][22]}

Still not publicly resolved

• The dispensing pharmacy for a specific Libida order
• The pharmacy’s 503A or 503B pathway for that order
• A complete Libida state-availability list
• Whether any lab or outside service will be required for a particular patient and what it will cost
• Product-specific pharmacokinetic or absorption data for the 1 mg sublingual bremelanotide component
• A controlled independent trial of the exact Libida combination, dose, and route
• A public protocol, comparator, endpoints, attrition table, and peer-reviewed report for the provider’s internal 10,000-plus-user claims
• A lot-level testing report, testing laboratory, methods, and acceptance limits
• Which conflicting price and HSA/FSA statement controls at a specific checkout
• What happens to payment if a clinician declines to prescribe after the charge is submitted

How we work

The HRT Index Verification Standard is our documented review process: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule—top providers monthly, the full roster quarterly. We evaluate providers on five things, in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. We do not publish invented numeric scores that hide the distinctions the reader came here to understand.

What must be rechecked after publication

Item	Refresh cadence	Verification method
Libida price, tablet count, discount, checkout charge, renewal	Monthly	Product page, pricing pages, dated checkout capture
Refund and cancellation terms	Monthly	Terms and refund-policy pages
HSA/FSA eligibility language	Monthly	Product page, FAQ, dedicated HSA/FSA page, written support confirmation
Formula and use limit	Quarterly or immediately after page change	Help-center FAQ and patient label
Pharmacy name and pathway	Quarterly and per documented order	Provider confirmation, pharmacy label, state license, FDA outsourcing-facility list if claimed
State availability	Quarterly	Provider state list or documented intake confirmation
FDA status and approved labels	Immediately after label or approval change	FDA/Drugs@FDA and DailyMed
Manufacturer assistance prices	Monthly on cost sections	Official Addyi and Vyleesi program terms
New Libida studies or pharmacokinetic data	Quarterly	PubMed, ClinicalTrials.gov, provider evidence page
Internal links and tool duration	Quarterly	Live site crawl and Find My HRT Path page

Frequently asked questions about Libida and FDA approval

Is Libida FDA-approved?

No. Libida is a compounded prescription product. FDA does not approve compounded drugs or review their safety, effectiveness, or quality before marketing.^[2]

Is PT-141 FDA-approved?

PT-141 is another name used for bremelanotide. FDA approved one specific bremelanotide product—Vyleesi, a 1.75 mg subcutaneous injection—for a defined premenopausal HSDD population. That approval does not extend to every form, dose, route, or combination containing bremelanotide.^[5]

Is Libida the same as Vyleesi?

No. Vyleesi is an FDA-approved bremelanotide injection. Libida is a compounded sublingual tablet that combines bremelanotide with oxytocin. They differ in dose, route, formulation, population, labeling, manufacturing pathway, and evidence.^[1][5]

Why is Libida a tablet if Vyleesi is an injection?

Compounding can create a dosage form that an approved product does not offer. Needle avoidance may be a real patient-specific reason to discuss that route. It is also why the injection’s absorption, adverse-event rates, and efficacy results cannot simply be assigned to the tablet.

What is the Libida dose?

Inner Balance’s June 2026 FAQ lists 1 mg bremelanotide and 20 IU oxytocin per tablet. It says not to use more than one dose in 72 hours and not to exceed 10 doses per month. Confirm those amounts and instructions on your own prescription label.^[1]

Is oxytocin FDA-approved for low libido?

No. Current FDA-approved oxytocin products are used for obstetric indications. We found no FDA-approved oxytocin product labeled for low desire and no FDA-approved sublingual oxytocin product.^[10]

Does compounded mean illegal?

No. Compounding can be lawful and clinically useful when applicable federal and state conditions are met. The legality and quality of a specific fill still depend on the prescriber, compounder, prescription, ingredients, and pathway; a marketing page alone cannot verify all of that.^[6][11]

Is Libida safe?

No public controlled study establishes the safety profile or incidence rates of the exact Libida tablet. Inner Balance lists nausea, flushing, headache, temporary blood-pressure elevation, and pigmentation among possible effects. Vyleesi’s label provides bremelanotide injection context, not Libida-specific rates.^[4][5]

Does Libida work?

Inner Balance publishes testimonials and internal claims, but we found no public controlled trial of the exact 1 mg bremelanotide + 20 IU oxytocin sublingual formulation. Vyleesi’s trials improved desire and distress versus placebo but did not show a significant difference in the change in satisfying sexual events.^[12]

Can postmenopausal women take Libida?

Inner Balance says clinicians may prescribe Libida across menopause stages after evaluation. Libida has no FDA-approved population and no public exact-product trial by menopause stage. Vyleesi’s premenopausal-only label does not automatically become Libida’s label, but it underscores why the evidence cannot be transferred.^[1][5]

Is there an FDA-approved treatment for low desire after menopause?

Addyi is FDA-approved for women under 65 with acquired, generalized HSDD meeting its label criteria, including postmenopausal women. It is a nightly pill with a boxed warning and important alcohol, drug-interaction, and liver-impairment restrictions.^[7]

Can I take Libida if an antidepressant lowered my libido?

Do not assume Libida is the right first answer. The approved HSDD labels exclude low desire caused by another medication. Bring the timing of the libido change and your full medication list to the prescriber; do not stop an antidepressant abruptly.^[5][7]

Is Libida a controlled substance?

Libida requires a prescription. The two publicly disclosed ingredients—bremelanotide and oxytocin—are not listed as federally scheduled controlled substances in the current federal schedules. Testosterone is different: it is Schedule III.^[9]

Does insurance cover Libida?

Inner Balance’s terms say the service is direct pay, does not accept insurance, and tells members not to submit claims to commercial or government insurance programs. Treat Libida as cash pay unless Inner Balance changes those terms in writing.^[16]

Is Libida HSA/FSA eligible?

The provider’s pages conflict. The product page says eligible, the Libida FAQ says it depends on the plan, and the dedicated HSA/FSA page says only Oestra is eligible. Get written confirmation from Inner Balance and your plan administrator before using pre-tax funds.^[1][4][17]

Can I get a refund on Libida?

Not under the current Inner Balance guarantee. The refund policy excludes Libida by name. Cancelling through the portal can stop future subscription participation; it does not create a refund for a Libida purchase already made.^[15][16]

Who compounds Libida?

Inner Balance does not name the dispensing pharmacy for a specific Libida order on the public pages we reviewed. Ask for the pharmacy’s legal name, license, location, and 503A or 503B status, then verify it through your state board and FDA’s list if a 503B claim is made.

Are labs included with Libida?

The public Libida flow does not identify a standard included lab panel or a universal lab requirement. Inner Balance’s terms allow clinicians to recommend outside tests or services that can create separate costs. Confirm any required test and price before payment.^[16]

Is Libida available in every state?

A complete public Libida state list was not found. Inner Balance’s terms say services may not be available everywhere. Confirm both prescriber licensure and pharmacy dispensing availability for your state before submitting a non-refundable charge.^[16]

The bottom line

Libida is not FDA-approved. It is a compounded prescription product containing provider-stated amounts of 1 mg bremelanotide and 20 IU oxytocin. That is lawful medicine when the applicable compounding rules are met—and medicine that does not carry an FDA-reviewed label, exact-product approval record, or public controlled trial.

One ingredient is in an approved product. That product is a 1.75 mg injection for premenopausal women with acquired, generalized HSDD. The approval belongs to that exact product. “Same active ingredient” tells you something about one molecule. It does not tell you what happens with a second ingredient, a lower stated dose, a tablet under the tongue, another manufacturing pathway, or a different patient population.

So the decision is not “approved good, compounded bad.” The real question is the one FDA’s compounding framework points toward: Can an approved option meet your need, or is there a patient-specific reason this compounded route makes more sense?

If you are premenopausal, Vyleesi and Addyi may be part of that conversation. If you are postmenopausal and under 65, Addyi now has a labeled path. If pain, dryness, a medication, mood, sleep, or another condition is driving the change, the right answer may not be a desire drug at all.

And if you and a prescriber decide Libida is the right fit, make the decision with the pharmacy named, the 1 mg + 20 IU label confirmed, the no-refund rule understood, the charge and renewal captured, the HSA/FSA contradiction resolved in writing, and the safety questions answered first.

That is not being difficult. That is how grown-ups buy medicine.

Still not sure which HRT program is right for you? Use Find My HRT Path for your free personalized starting-point plan.

---

Sources

¹ Inner Balance Help Center, “Libida Frequently Asked Questions,” dated June 14, 2026.

² U.S. Food and Drug Administration, “Compounding and the FDA: Questions and Answers”.

³ U.S. Food and Drug Administration, “FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs,” June 15, 2026.

⁴ Inner Balance, Libida product page, verified August 2026.

⁵ DailyMed, Vyleesi (bremelanotide injection) prescribing information, updated November 13, 2025.

⁶ U.S. Food and Drug Administration, Human Drug Compounding.

⁷ DailyMed, Addyi (flibanserin) prescribing information, current label verified August 2026.

⁸ Davis SR, et al., “Global Consensus Position Statement on the Use of Testosterone Therapy for Women”, Journal of Clinical Endocrinology & Metabolism, 2019.

⁹ Electronic Code of Federal Regulations, 21 CFR § 1308.13 — Schedule III.

¹⁰ DailyMed, Oxytocin injection drug labels, current products verified August 2026.

¹¹ U.S. Food and Drug Administration, Section 503A guidance on essentially copies of commercially available drugs.

¹² Kingsberg SA, et al., “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials”, Obstetrics & Gynecology, 2019.

¹³ Muin DA, et al., “Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial”, Fertility and Sterility, 2015.

¹⁴ Inner Balance, “How Much Do Female Libido Treatments Cost? Pricing Guide 2026”, verified August 2026.

¹⁵ Inner Balance, Refund Policy, verified August 2026.

¹⁶ Inner Balance, Terms of Use and Subscription Terms, verified August 2026.

¹⁷ Inner Balance, HSA/FSA page, verified August 2026.

¹⁸ Addyi official site, Getting Addyi and current manufacturer pricing, verified August 2026.

¹⁹ Vyleesi official site, current access and savings information, verified August 2026.

²⁰ Inner Balance, About Us — pharmacy-quality disclosures, verified August 2026.

²¹ Inner Balance, Oestra product page — 503B facility statement, verified August 2026.

²² Inner Balance, “Low Sex Drive Medication: Brain-Based Solutions” — conflicting Libida 20-tablet charge, verified August 2026.